Autobahn Therapeutics raised $100 million in a Series C this week, pledging to use the new funding for its pipeline of drug candidates for depression and other central nervous system disorders.

Autobahn Therapeutics’ platform technology enables small molecules to selectively hit targets in the brain. In addition to a lead program ready for Phase 2 testing in two types of depression ...

"By leveraging USC's scientific expertise and Autobahn's drug discovery capabilities, we are accelerating the development of novel therapeutics that address critical medical needs and improve ...